Corrections

Full results on risks of epoetin emerge 14 years after major dialysis study

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e3677 (Published 25 May 2012) Cite this as: BMJ 2012;344:e3677

This News story (BMJ 2012;344:e3535, doi:10.1136/bmj.e3535) incorrectly stated that the normal haematocrit trial “formed the basis for regulatory approval” of the drug epoetin alfa. In fact, epoetin alfa had already been approved for use in the US.

Notes

Cite this as: BMJ 2012;344:e3677

View Abstract